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Abstract: Several photodynamically-active substances and farnesyltransferase inhibitors 
are currently being investigated as promising anticancer drugs. In this study, the combined 
effect of hypericin (the photodynamically-active pigment from Hypericum perforatum) and 
selective farnesyltransferase inhibitor manumycin (manumycin A; the selective 
farnesyltransferase inhibitor from Streptomyces parvulus) on HT-29 adenocarcinoma cells 
was examined. We found that the combination treatment of cells with photoactivated 
hypericin and manumycin resulted in enhanced antiproliferative and apoptotic response 
compared to the effect of single treatments. This was associated with increased suppression 
of clonogenic growth, S phase cell cycle arrest, elevated caspase-3/7 activity and   
time-dependent total cleavage of procaspase-3 and lamin B, cleavage of p21Bax into 
p18Bax and massive PARP cleavage. Moreover, we found that the apoptosis-inducing 
factor is implicated in signaling events triggered by photoactivated hypericin. Our results 
showed the relocalization of apoptosis-inducing factor (AIF) to the nuclei after hypericin 
treatment. In addition, we discovered that not only manumycin but also photoactivated 
hypericin induced the reduction of total Ras protein level. Manumycin decreased the 
amount of farnesylated Ras, and the combination treatment decreased the amount of both 
farnesylated and non-farnesylated Ras protein more dramatically. The present findings 
indicate that the inhibition of Ras processing may be the determining factor for enhancing 
the antiproliferative and apoptotic effects of combination treatment on HT-29 cells. 
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1. Introduction 
Hypericin is a photodynamic pigment first isolated from the plant Hypericum perforatum L., 
commonly known as St. John’s Wort [1]. The term “photodynamic” means that hypericin as a 
component of photodynamic therapy becomes activated by visible light at the proper wavelength   
(570–650 nm) in the presence of molecular oxygen. The subsequent generation of singlet oxygen and 
superoxide anions, led to oxidative damage and destruction of cancer cells [2,3].  
Treatment with hypericin-mediated photodynamic therapy is under investigation for several cancer 
and non-cancerous diseases. In an effort to improve the treatment effectiveness, various combination 
approaches have been investigated. Our previous studies showed increased apoptosis of various cancer 
cell lines when hypericin-mediated photodynamic therapy was combined with 5-LOX inhibitor [4], 
P450 monooxygenase inhibitor [5], genistein [6] and polyunsaturated fatty acids [7]. The effectiveness 
of hypericin-mediated photodynamic therapy was improved by the use of PD169316, a p38α MAPK 
inhibitor in human cervix carcinoma cells and human bladder cancer cells [8] and by diazepam in 
glioma cells [9]. Hypericin was able to enhance radiosensitivity in human malignant glioma cells and 
human renal carcinoma cells [10,11] and the antiglioma effects of temozolomide by inducing apoptosis 
both in vitro and in vivo [12]. The combination of hypericin-mediated photodynamic therapy with 
hyperthermia enhanced RIF-1 tumor cell killing by triggering apoptosis [13]. Bhuvaneswari et al. 
documented increased apoptosis associated with bladder tumor inhibition using the combination of 
hypericin-mediated photodynamic therapy with angiogenesis inhibitors [14].  
Manumycin A (UCF1-C) is a natural product from Streptomyces parvulus that acts as a potent and 
selective Ras farnesyltransferase inhibitor [15]. The enzyme farnesyltransferase modifies Ras and 
other proteins with the farnesyl isoprenoid lipid that is required for their correct cellular localization 
and biological activity [16].  
Recently, the
 anti-neoplastic activity of manumycin has been demonstrated in various experimental 
systems. Manumycin-induced apoptosis of human pancreatic cancer cells [17], anaplastic thyroid cancer 
cells [18,19], human colon tumor cells [20],  human hepatocellular carcinoma HepG2 cells [21], 
medulloblastoma cells [22,23], leukemic U937 and HL-60 cells [24], lymphoid tumor and myeloma 
cell lines [25,26]. 
Several studies have demonstrated the enhanced cytotoxic or apoptotic effects on various cancer 
cell lines as a consequence of the combination of manumycin and paclitaxel [18], methoxyamine [27] 
and HSP inhibitor quercetin [28]. The combination of manumycin and paclitaxel and the triple-drug 
combination of manumycin, paclitaxel and minocycline were effective also in vivo against anaplastic 
thyroid carcinoma [29,30]. 
In this work, the effective combination of photodynamically-active drug and selective 
farnesyltransferase inhibitor was investigated for the first time. Besides an enhanced antiproliferative 
and apoptotic response of HT-29 cells to combination treatment with photoactivated hypericin and Int. J. Mol. Sci. 2011, 12                 
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manumycin, we also discovered new players in the signaling machinery triggered by photoactivated 
hypericin, namely an apoptosis-inducing factor (AIF) and Ras.  
Our results indicate the possibility of new effective combination of two natural products, the 
photodynamically-active drug and farnesyltransferase inhibitor, as a new modality approach for 
anticancer therapies in the future.  
2. Results and Discussion 
In this study, colon adenocarcinoma cells HT-29 were exposed to combination treatment with 
photoactivated hypericin and Ras farnesyltransferase inhibitor manumycin. Hypericin was used at a 
concentration of 100 nM, which induces apoptosis and G2 phase arrest of HT-29 cells under defined 
conditions of the photodynamic protocol, as we demonstrated in our previous study [31]. Manumycin 
at a concentration of 15 µM was added to cells 1 h before hypericin photoactivation. As the results of 
MTT assay showed, this concentration was not cytotoxic for the cells and it did not modify the effect 
of hypericin as determined by MTT values of the combination treatment (Figure 1).  
Figure 1. MTT assay. Cells were treated with drugs (HY—hypericin, Manu—manumycin) 
as indicated or left untreated (Control), and MTT assay was performed 24 h after hypericin 
photoactivation. All data are expressed as mean ± SEM from three independent experiments 
(** p < 0.01 compared to control). 
 
In contrast to MTT, the cells showed decreased colony-forming capacity after manumycin treatment 
and also after hypericin treatment compared to untreated control. The combination treatment led to 
enhanced inhibition of colony formation compared to treatment with hypericin or manumycin alone 
(Figure 2). The different mechanisms involved in each assay probably explain the discrepancy between 
the MTT and clonogenic assay results, i.e., short-term cytotoxicity in the MTT assay and long-term 
proliferation and clonogenic survival in the clonogenic assay [32].  Int. J. Mol. Sci. 2011, 12                 
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Figure 2. Colony-forming assay. Cells were treated with drugs (HY—hypericin,   
Manu—Manumycin) as indicated or left untreated (Control). After the treatments, equal 
numbers of viable cells (500/well) were seeded into 6-well plates containing RPMI-1640 
and FBS (10%) and allowed to grow under standard conditions for 10 days. Colonies were 
stained using methyl blue solution. All data are expressed as mean ± SEM from three 
independent experiments. 
 
To determine whether cell cycle arrest contributed to the decreased cell proliferation observed after 
combination therapy, cell cycle analysis using flow cytometry was performed. The data on cell cycle 
distribution (Figure 3) revealed that cells treated with the drug combination were accumulated in the 
S phase (51.59% versus 41.03% in control) as well as cells treated with manumycin (48.17% versus 
41.03% in control) or hypericin alone (53.46% versus 41.03% in control) at 6 h. Cells treated with 
manumycin alone (46.65% versus 35.79% in control) and with combination (49.47% versus 35.79% in 
control) also remain accumulated in the S phase after longer incubation period (24 h). In cells treated 
with hypericin, the early S phase arrest disappeared and cells were arrested in the G2 phase of cell 
cycle at 24 h (25.05% versus 11.71% in control). This means that hypericin-treated cells passed 
through the S phase and were subsequently blocked in G2 phase arrest. Although hypericin alone led 
to G2 arrest, the cells treated with the combination did not arrest in G2 but accumulated in the S phase. 
These results demonstrate that accumulation of cells in the S phase after the combination treatment is 
significant compared to hypericin alone, but the cell cycle distribution is the same as the pattern 
induced by manumycin alone. Moreover, the disappearance of both S and G2 arrests induced by 
hypericin at the later time points indicate that these processes are reversible. In contrast, the 
manumycin-caused S phase arrest was irreversible and sustained from early to later analysis time points.  
Previous works of our research group have documented G2 phase arrest after hypericin treatment  
in HT-29 cells [31] and hypericin plus genistein treatment in MCF-7 cells [6], S  phase arrest in 
hypericin-treated U937 cells [31] and S phase arrest also with accumulation of cells in the G0/G1 
phase induced by combination of hypericin and LOX inhibitor MK-886 [4]. Increased subdiploid 
G0/G1 population of HL-60 cells was detected after hypericin plus acetazolamide treatment [33]. 
Vantieghem et al. reported G2/M phase-arrested HeLa cells following photodynamic therapy with 
hypericin [34].  Int. J. Mol. Sci. 2011, 12                 
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Figure 3. Cell cycle distribution. Cells were treated with drugs (HY—hypericin,   
Manu—Manumycin) as indicated or left untreated (Control), and cell cycle analysis using 
flow cytometry was performed at 6 and 24 h after hypericin photoactivation. All data   
are expressed as mean ± SEM from three independent experiments (** p < 0.01,   
*** p < 0.001; 
●●● p < 0.001). 
 
Manumycin A had no effect on the cell cycle of medulloblastoma cells [22]. In contrast, HepG2 
cells were accumulated in the G2/M of the cell cycle after treatment with manumycin in the study by 
Zhou et al. [21]. These reports indicate that different mechanisms for hypericin or manumycin induced 
cytotoxicity may be involved in different cancer cell types. 
The results of cell cycle distribution are consistent with the growth inhibition detected by   
colony-forming assay, suggesting that the antiproliferative effect of drugs alone and in combination is 
associated with S phase arrest and apoptosis of cells. It has been reported that both arrest and death 
preclude outgrowth of colonies [35]. 
Each of the apoptotic signaling pathways converges to a common execution phase of apoptosis that 
requires proteolytic activation of caspases-3 and/or -7 from their inactive zymogens. Measurement of 
caspase-3/7 activity in a  fluorometric assay revealed elevated enzyme activity after combination 
treatment (Figure 4). The results showed that combination treatment induced statistically significant 
time-dependent increase in caspase-3/7 activation at 3 and 6 h time points compared to control and 
hypericin or manumycin alone. Treatment of cells with hypericin and manumycin alone elevated 
caspase-3/7 activity as early as 1 h compared to control, and it remained elevated above control at 6 h 
and 24 h. Caspase-3/7 activation was completely eliminated by pan-caspase inhibitor Z-VAD-FMK.  Int. J. Mol. Sci. 2011, 12                 
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Figure 4. Caspase-3/7 activity. Cells were treated with drugs (HY—hypericin,   
Manu—Manumycin) as indicated or left untreated (Control), and caspase-3/7 activity was 
measured using Apo-One™ homogenous caspase-3/7 assay at various times after hypericin 
photoactivation. All data are expressed as mean ± SEM from three independent 
experiments as ratios to untreated control values (* p < 0.05, ** p < 0.01, *** p < 0.001;  
● p < 0.05, 
●● p < 0.01; 
■ p < 0.05, 
■■■ p < 0.001). 
 
To determine whether the decreased proliferation activity of cells and increased caspase activity 
after combination treatment were associated with the induction of apoptosis, the apoptotic proteins 
were analyzed using western blotting (Figure 5A). As the results show, the long incubation period  
(24 h) revealed the enhanced effect of hypericin plus manumycin treatment on the analyzed proteins 
compared to single treatments.  
Manumycin alone or manumycin plus hypericin treatment caused more rapid proteolytic cleavage 
of PARP associated with accumulation of an 89-kDa fragment than hypericin alone. The 89-kDa 
PARP fragment was detected as early as 6 h after manumycin and combination treatment. Most of the 
116-kDa PARP was degraded at 24 h in cells treated with hypericin plus manumycin. At that time of 
analysis, a massive 89-kDa PARP fragment occurred simultaneously with complete cleavage of the  
67-kDa lamin B, which generated a fragment of 45 kDa, total processing of procaspase-3 (35-kDa) and 
appearance of a p18 fragment of Bax in cells treated with the combination of drugs. The cleavage 
fragment of Bax was weakly detected also in manumycin-treated cells. Interestingly, in cells treated 
with manumycin and hypericin plus manumycin, another fragment of PARP corresponding to ~43 kDa 
was observed along with the usual ~89 kDa.  
The cleavage of full-length p21 Bax into proapoptotic p18 Bax is described in several studies [36–38]. 
According to published data, cleavage of full-length Bax into proapoptotic p18 Bax is mediated by 
calpain [39–41] and results in acceleration of apoptotic cell death [42,43].  Int. J. Mol. Sci. 2011, 12                 
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Figure 5. Western blot analysis of apoptosis-related proteins (A,B) and total Ras (C) in 
whole cell extracts prepared at indicated time periods after the various treatments. Cells 
were incubated with the general caspase inhibitor Z-VAD-FMK at a concentration of 
50 μM for 2  h prior to hypericin photoactivation (B). The immunoblots shown here 
represent three independent experiments with similar results. β-actin (Actin) was employed 
as the loading control. (NF—non-farnesylated, F—farnesylated). 
 
To determine whether caspases were involved in cleavage of proteins, cells were pretreated   
with the broad-spectrum caspase inhibitor Z-VAD-FMK. As shown in Figure 5B, pre-treatment of 
cells with Z-VAD-FMK completely blocked hypericin-induced PARP cleavage into the ~89 kDa 
fragment. In manumycin-treated cells PARP cleavage was prevented only at the 3 and 6 h analyses, 
but the inhibitor had no effect on manumycin-induced PARP and lamin B cleavage at the 24 h analysis. 
Cleavage of PARP into the smaller ~43 kDa fragment was blocked by general pan-caspase inhibitor in 
cells treated with the combination of drugs, but not in manumycin-treated cells. This is the first 
evidence about caspase-independent PARP and lamin B cleavage alike in manumycin-induced   
caspase-dependent apoptosis.  Int. J. Mol. Sci. 2011, 12                 
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Proteolytic cleavage of 116-kDa polypeptide PARP to its characteristic 89-kDa fragment is known 
as a typical marker of apoptosis. Although this cleavage is largely mediated by a number of caspases, 
recent studies have demonstrated caspase-independent PARP cleavage in TGF-β-induced  
caspase-dependent apoptosis of AML-12 cells and in MBP-1-induced lung cancer cell death [44,45]. 
In the study by Bhaskara et al. [46] apoptotic cell death led predominantly to the appearance of the 
larger ~89 kDa fragment and smaller ~24 kDa fragment, but also other fragments were formed 
indicating other forms of cell death. PARP-1 is also a preferred substrate for the proteolytic action of 
calpains and cathepsins that give rise to ~40 kDa fragments [47]. Since the cleavage of PARP into the 
smaller ~43 kDa fragment was blocked by general pan-caspase inhibitor in cells treated with the 
combination of drugs, we suppose that calpain is not involved in this process. In contrast, the ~43 kDa 
fragment of PARP detected in manumycin-treated cells was not eliminated by Z-VAD-FMK. This 
result may indicate the co-existence of various intermediate cell death pathways [46]. 
The lamins represent a key substrate for the proteases activated during apoptosis, whose 
degradation facilitates the nuclear events of apoptosis [48]. Proteolysis of lamin B has been observed 
in various cells undergoing apoptosis after different insults [49–53]. Lamin B was proteolyzed during 
apoptosis of HepG2 cells induced by manumycin [21]. The involvement of caspases in this process 
was not investigated. In our study, lamin B cleavage was not blocked by pan-caspase inhibitor in 
manumycin-treated cells, indicating that this process is not dependent on caspases and could also be 
achieved through proteases other than caspases. Zhivotovsky et al. demonstrated the involvement of at 
least two proteases in lamin cleavage [54]. Neither of them cleaved PARP, so they concluded that 
lamin and PARP cleavage during apoptosis are distinct processes mediated by different proteases.  
However, PARP, lamin B and Bax cleavage together with procaspase 3 processing were completely 
blocked by pan-caspase inhibitor in cells treated with hypericin plus manumycin. These results along 
with inhibition of caspase-3/7 activity by Z-VAD-FMK indicate that the enhanced apoptotic response 
induced by combination treatment is realized via a caspase-dependent pathway.  
To further elucidate the mechanism of enhanced apoptosis induced by combination treatments, the 
possibility of involvement of apoptosis-inducing factor (AIF) was examined. AIF is a pro-apoptotic 
mitochondrial intermembrane flavoprotein that is translocated to the nucleus and causes chromatin 
condensation in response to various stimuli including some photosensitizers [55–58].  
In our study, apoptosis-inducing factor was translocated to the nucleus as an early response of 
cancer cells to hypericin treatment, but not to manumycin treatment. Immunofluorescence analysis 
revealed changes in nuclear morphology at 3 h following hypericin photoactivation. As demonstrated 
by DAPI staining, the typical condensed and fragmented apoptotic nuclei were detected. AIF staining 
revealed diffuse distribution in the cytosol and peripheral areas of condensed apoptotic nuclei of 
hypericin-treated cells, compared to granular pattern in the cytosol of untreated cells and also cells 
treated with manumycin or combination. This observation proves the translocation of AIF into the 
nuclei after hypericin photoactivation (Figure 6A), and it was also confirmed by Western blot analysis 
of the cytosolic and nuclear fraction. The results show that hypericin induces the relocalization of AIF to 
the nucleus. The level of AIF was elevated as early as 1 h after PDT and continued to increase for a 3 h 
period. The amount of AIF in the nuclear fraction remained elevated at 6 and 24 h compared to 
untreated cells (Figure 6B). These results indicate that caspases and AIF can function in parallel in Int. J. Mol. Sci. 2011, 12                 
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hypericin but not in manumycin or combination-triggered apoptotic signaling events. To our 
knowledge, this is the first report about the involvement of AIF in hypericin photodynamic action. 
Figure 6. Relocalization of AIF to the nucleus. Cells were treated with drugs as indicated 
or left untreated (C; Control), and immunofluorescent staining protocol was performed at  
3 h after hypericin photoactivation. Cells were stained with DAPI to visualize the nuclei 
(blue fluorescence). Cells were immunostained with an anti-AIF polyclonal antibody 
(green fluorescence) (A). Translocation of AIF was examined by western blotting of the 
cytosolic and nuclear fractions at various times after hypericin photoactivation. Equivalent 
protein loading was confirmed by appropriate loading markers (B). 
 
Based on the fact that manumycin can acts as Ras inhibitor, it was of interest to examine whether 
hypericin can affect Ras as well. Determination of the level of total Ras by western blotting with anti 
pan-Ras antibody showed that hypericin reduced the level of both farnesylated (F) and non-farnesylated 
(NF) Ras at the 24 h analysis (Figure 5C). These results demonstrate for the first time the involvement 
of Ras in photoactivated hypericin signaling. To our knowledge, only one study exists that reports a 
decrease in Ras protein level triggered by Rose Bengal-mediated photodynamic treatment in HUVECs. 
In agreement with others [20–22,59], treatment with manumycin alone caused a decrease in Int. J. Mol. Sci. 2011, 12                 
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farnesylated Ras protein. Furthermore, since HT-29 expresses a normal K-ras gene, our results support 
the findings of Di Paolo et al. that manumycin is able to suppress the proliferation of tumor cells with 
wild-type K-ras genes [20]. Changes in Ras level detected after combination treatment showed the 
time-dependent effect of both agents. The amount of both bands of Ras was reduced at all time points, 
but more pronounced decrease was noticed at the 24 h analysis.  
Collectively, these findings suggest that the enhanced antiproliferative and apoptotic response of 
HT-29 adenocarcinoma cells after combination treatment is a consequence of strong decrease in total 
Ras protein, which is a common target of both photoactivated hypericin and manumycin action. 
Further investigations are required to determine the signaling events downstream of Ras. 
3. Experimental Section  
3.1. Cell Culture  
The human colon adenocarcinoma cell line HT-29 (American Type Culture Collection, Rockville, 
MD, USA) was cultured in RPMI-1640 medium (Gibco, Grand Island, NY, USA) supplemented with 
10% fetal bovinne serum (FBS; Invitrogen Corp., Carlsbad, CA, USA) and antibiotics (penicillin   
100 U/mL, streptomycin 100 μg/mL and amphotericin 25 μg/mL; Invitrogen Corporation, Carlsbad, 
CA, USA). Cells were maintained at 37 °C in a humidified 5% CO2 atmosphere.  
3.2. Reagents  
Hypericin (4,5,7,4′,5′,7′-hexahydroxy-2,2′-dimethylnaphtodiantron, HPLC grade) was purchased 
from AppliChem GmbH (Darmstadt, Germany); MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide), manumycin A from Streptomyces parvulus and Z-VAD-FMK   
(N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone) were obtained from Sigma-Aldrich 
Corporation (St. Louis, MO). Both hypericin and manumycin were prepared in DMSO as stock 
solutions stored at −20 °C (hypericin at 1 mM concentration; manumycin at 10 mM concentration) and 
then diluted to a  working solution of final concentration (hypericin at 100 nM concentration; 
manumycin at 15 μM concentration). The final concentration of DMSO was less than 0.1% and did not 
influence the cytokinetic parameters. 
3.3. Experimental Design  
HT-29 cells were seeded and cultivated for 24 h in a complete medium RPMI-1640 with 10% FBS. 
Next, cells were treated according to the time schedule (Scheme 1). The crucial point of the whole 
experimental design was the time of hypericin photoactivation (0 h). 
3.4. Hypericin Treatment 
Cells were incubated for 16 h with 100 nM hypericin in dark conditions before light activation with 
a single light dose (4.4 J·cm
−2). The control group received a medium with serum without hypericin. 
Following hypericin photoactivation cells were incubated at 37 °C in dark conditions for the indicated 
times and separate analyses were performed. Int. J. Mol. Sci. 2011, 12                 
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Scheme 1. Experimental time schedule (h). Cells were seeded (−40 h) and cultivated for  
24 h in a complete medium. Next, hypericin was added (−16 h) and photoactivated (0 h).  
Z-VAD-FMK and manumycin were added at 2 h and 1 h respectively before   
hypericin photoactivation. Analyses were performed at 1 h, 3 h, 6 h and 24 h after   
hypericin photoactivation. 
 
3.5. Manumycin Treatment 
Inhibitor manumycin (15 μM) was added to cells 1 h prior to hypericin photoactivation.  
3.6. Pan-Caspase Inhibitor Treatment 
Cells were incubated with the general caspase inhibitor Z-VAD-FMK at a concentration of 50 μM 
for 2 h prior to hypericin photoactivation.  
3.7. Hypericin Photoactivation  
Plates with the cells were placed on a plastic diffuser sheet above a set of nine L18W/30 lamps 
(Osram, Berlin, Germany) with maximum emission between 530 and 620 nm (the absorption peak of 
hypericin is 595 nm). At the surface of the diffuser the uniform fluence rate was 4.4 mW·cm
−2·s
−1 and 
the temperature did not exceed 37 °C. 
3.8. MTT Assay 
Cells were seeded in 96-well tissue culture plates (1 × 10
4 cells/well). After the treatments, MTT  
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; Sigma-Aldrich Corporation) was 
added to cells at the analysis time point (24 h after hypericin photoactivation) and after 4 h incubation 
the metabolization of MTT was stopped and crystals of formazan were dissolved overnight with   
10% SDS (final concentration 3.3%) (Serva, Heidelberg, Germany). The amount of dissolved formazan 
was quantified by absorbance measurements at 584 nm (FLUOstar Optima, BMG Labtechnologies 
GmbH, Offenburg, Germany) and expressed as a percentage of the dye extracted from untreated control 
cells ((OD value of treated cells/mean OD value of control cells) × 100%). Int. J. Mol. Sci. 2011, 12                 
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3.9. Colony-Forming Assay 
To determine colony formation, cells were seeded into 6-well tissue culture plates (2 × 10
6 cells/well) 
and treated according to the experimental design for 24 h. After this period, cells were trypsinized, 
collected and washed twice with fresh medium. Equal numbers of viable cells (500/well) were then 
seeded into 6-well tissue culture plates containing RPMI-1640 and FBS (10%) and allowed to grow 
under standard cultivation conditions until visible colonies were observed. Colonies were stained using 
methyl blue staining.  
3.10. Cell Cycle Distribution Analysis 
For DNA content, cells were harvested, washed with phosphate-buffered saline (PBS) and fixed 
with 70% ice-cold ethanol at −20 °C. Fixed cells were centrifuged, washed with PBS and stained with 
staining solution (5 mg/mL propidium iodide, 10 mg/mL RNase A and 10% Triton X-100 in PBS). 
Then samples were kept in dark conditions for 30 min and measured on a flow cytometer (FACS 
Calibur, Becton Dickinson, San Diego, CA). For each sample, 15,000 cells were evaluated and the 
sample flow rate during analysis did not exceed 200–300 cells per second. The data obtained were 
analyzed using the Cell Quest Pro software.  
3.11. Caspase-3/7 Activity Assay 
Caspase-3/7 activity was measured using Apo-ONE™ Homogeneous Caspase-3/7 Assay (Promega 
Corporation, Madison, WI, USA) based on the cleavage of the non-fluorescent caspase substrate   
Z-DEVD-R110 by caspase-3/7 to create fluorescent Rhodamine 110. Experiments were performed 
according to the protocol provided by the manufacturer.  After the treatments according to the 
experimental design, the homogeneous caspase-3/7 reagent was added to the 2 × 10
4 cells/sample. 
Following incubation at room temperature for 2 h, caspase-3/7 activity was estimated from the 
fluorescence measured using a fluorescence microplate reader (excitation at 499 nm, emission at   
521 nm; FLUOstar Optima). 
3.12. Western Blot Analysis  
For preparation of whole cell lysates, 2 × 10
6 cells/well were seeded into 6-well microplates and 
treated in accordance with the experimental protocol. Harvested cells were washed in cold PBS and 
lysed in lysis buffer (100 mM Tris-HCl, pH 7.4, 1% SDS, 10% glycerol) with protease inhibitor 
cocktail (P2714; Sigma-Aldrich Corporation) for 10 min on ice. The cell lysates were sonicated and 
centrifuged. Protein concentration was determined using detergent compatible protein assay (BioRad 
Laboratories Inc., Hercules, CA, USA). Equal amounts of proteins (30 µg) were diluted in sample 
buffer (1 M Tris-HCl, 10% SDS, 1% 2-mercaptoethanol, 1% bromphenol blue and 50% glycerol), 
separated in SDS-polyacrylamide gel and transferred onto PVDF membrane (Millipore, Bedford, MA, 
USA) in a transfer buffer containing 192 mM glycine, 25 mM Tris and 10% methanol. After 
membrane blocking (1 h at RT) in 5% non-fat milk in TBS-Tween (20 mM Tris-HCl, pH 7.6;   
150 mM NaCl; 0.05% TWEEN 20, pH 7.4) the PVDF membrane blots were incubated with the 
primary (1 h at RT or overnight at 4 °C) and secondary antibodies (1 h at RT). Blots were developed Int. J. Mol. Sci. 2011, 12                 
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with ECL western blotting substrate (Pierce Biotechnology, Inc., Rockford, IL, USA) and visualized 
on X-ray films (AGFA-gevaert N.V., Kontich, Belgium).  
3.13. Cytosolic and Nuclear Fractionation 
The extraction of nuclear and cytoplasmic protein fractions was performed with the 
Nuclear/Cytosol Fractionation Kit (BioVision Research Products, Mountain View, CA, USA) in line 
with the protocol provided by the manufacturer.  
3.14. Antibodies 
Primary antibodies included mouse monoclonal anti-caspase-3 (E-8, 1:1000),  rabbit polyclonal   
anti-PARP (H-250, 1:1000), rabbit polyclonal anti-Bax (1:1000), goat polyclonal anti-Lamin B   
(M-20, 1:200) and goat polyclonal anti-histone H1 (N-16, 1:1000) purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA, USA); rabbit polyclonal anti-AIF (1:1000) from Cell Signaling 
Technology, Inc. (Danvers, MA, USA), mouse monoclonal anti-β-actin (1:1000) from Sigma-Aldrich 
Corporation (St.Louis, MO, USA), and mouse monoclonal anti-Pan-Ras (Ab-3, 1:100) from 
Calbiochem (Merck KGaA, Darmstadt, Germany). Horseradish peroxidase-conjugated  secondary 
antibodies (anti-mouse IgG 1:5000, anti-rabbit IgG 1:5000, anti-goat IgG 1:5000) were obtained from 
Pierce Biotechnology, Inc. (Rockford, IL, USA). 
3.15. Immunofluorescent Staining of AIF  
At the indicated time after treatment, cells grown on cover slips were fixed with paraformaldehyde, 
permeabilized with 0.3% Triton X-100 and incubated with blocking solution containing 0.1% bovine 
serum albumin (BSA) in PBS. After washing with 8% BSA, cells were incubated overnight at 4 °C 
with primary antibody (1:100; rabbit polyclonal AIF, Santa Cruz Biotechnology, Inc.), diluted in 0.1% 
Triton X-100 in PBS (PBS-T) and then with secondary antibody (1:300; goat anti-rabbit IgG-FITC; 
Santa Cruz Biotechnology, Inc.). Cells were then washed with PBS and incubated at room temperature 
with DAPI (4′,6-diaminidino-2-phenyl-indole, dihydrochloride; 1 μg/mL) for nuclear visualization. 
After washing the cells with PBS, the coverslips were mounted on slides with MOWIOL and 
examined with fluorescence microscope (Leica DMI 6000 B, Leica Microsystems, Inc., Bannockburn, 
IL, USA). 
3.16. Statistical Analysis 
Data were processed with GraphPad Prism (GraphPad Software Inc., San Diego, CA, USA) and 
statistically analyzed using one-way ANOVA followed by Tukey’s multiple comparison test. All 
experimental groups were compared to control (* p < 0.05, ** p < 0.01, *** p < 0.001), and the groups 
with combination treatment were compared to the groups treated with hypericin alone (
● p < 0.05,  
●● p < 0.01, 
●●● p < 0.001) or manumycin alone (
■ p < 0.05, 
■■ p < 0.01, 
■■■ p < 0.001). Int. J. Mol. Sci. 2011, 12                 
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4. Conclusions 
To sum up, in this study we report for the first time how the combination of photosensitive drug 
(hypericin) and farnesyltransferase inhibitor (manumycin) leads to increased antiproliferative and 
apoptotic response of adenocarcinoma cells HT-29 associated with reduced Ras protein levels. 
Enhanced apoptosis after combination treatment was demonstrated by elevated caspase-3/7 activity 
and time-dependent total cleavage of procaspase-3 and lamin B, cleavage of p21Bax into p18Bax and 
massive PARP cleavage. In addition, we discovered that Ras and AIF are new players in photoactivated 
hypericin action. 
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